Patents by Inventor Darrow E. Haagensen, Jr.

Darrow E. Haagensen, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of determining the risk of breast cancer development
    Patent number: 5648224
    Abstract: This invention relates to a method of determining, in a subject having active breast gross cystic disease, the risk of future breast cancer development. The level of glycoprotein GCDFP-15 in the plasma is measured at the time of cyst aspiration in order to provide an indication as to the likelihood of future breast cancer development.
    Type: Grant
    Filed: August 15, 1995
    Date of Patent: July 15, 1997
    Inventor: Darrow E. Haagensen, Jr.
  • Breast cyst fluid protein assay
    Patent number: 4452904
    Abstract: This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDFP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.
    Type: Grant
    Filed: August 13, 1981
    Date of Patent: June 5, 1984
    Assignee: Duke University
    Inventor: Darrow E. Haagensen, Jr.
  • Breast cyst fluid protein assay
    Patent number: 4440863
    Abstract: This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDEP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.
    Type: Grant
    Filed: August 13, 1981
    Date of Patent: April 3, 1984
    Assignee: Duke University
    Inventor: Darrow E. Haagensen, Jr.
  • Breast cyst fluid protein assay
    Patent number: 4229426
    Abstract: This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDFP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.
    Type: Grant
    Filed: February 22, 1978
    Date of Patent: October 21, 1980
    Assignee: Duke University, Inc.
    Inventor: Darrow E. Haagensen, Jr.